This study is testing a medication called Recombinant Factor VIIa (rFVIIa) to see if it can improve outcomes for people who have had a hemorrhagic stroke (bleeding in the brain). Researchers want to find the best time to give rFVIIa and to which patients it might be most helpful. You might be eligible if you are between 18 and 80 years old, have had a spontaneous intracerebral hemorrhage, and can receive the study medication within a specific timeframe. A key part of eligibility is having a "spot sign" on a CT scan or being treated very quickly after your stroke. The main goal is to see if rFVIIa improves your recovery at 90 days, as measured by a scale called the Modified Rankin Scale. The study is currently recruiting up to 350 participants.

Study design

This is a global, randomized, double-blind study comparing rFVIIa to a placebo, along with standard medical care. Approximately 350 participants will be enrolled.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your recovery will be measured at 90 days after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.